Baxter and Coherus amend biosimilar etanercept collaboration

Biosimilars/News | Posted 29/05/2015 post-comment0 Post your comment

US-based biosimilars developer Coherus BioSciences (Coherus) and Baxter International (Baxter) announced on 15 April 2015 that they had amended some of the financial terms of their collaboration agreement for CHS-0214, an etanercept biosimilar candidate.

Shaking hands V13D29

The two companies made an exclusive collaboration agreement in September 2013 to develop and commercialize an etanercept biosimilar for Brazil, Canada, Europe and certain other markets [1].

Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In total, the revised milestone payments may exceed the previous Baxter funding obligations by approximately US$12 million. Baxter has also agreed to purchase Coherus common stock in a private placement transaction.

‘With this amended agreement, we will continue to advance development of the etanercept biosimilar program[me] and begin preparations for eventual commercialization in Europe,’ said Dagmar Rosa-Björkeson, global head of biosimilars for Baxter BioScience.

Coherus announced in October 2013 that its etanercept biosimilar (CHS-0214) had met the primary endpoint of clinical pharmacokinetic similarity to the originator biological Enbrel (etanercept) in a confirmatory clinical study in healthy subjects [2]. This was followed by the start of a global phase III trial to evaluate the efficacy and safety of CHS-0214 compared to Amgen’s blockbuster arthritis treatment Enbrel (etanercept) in subjects with rheumatoid arthritis. Coherus is also planning another phase III trial with its biosimilar etanercept candidate (CHS-0214) in patients with chronic plaque psoriasis, according to [3].

Related articles
Biosimilars of etanercept

Biosimilars developer Coherus raises US$55 million investment

1.   GaBI Online - Generics and Biosimilars Initiative. Baxter and Coherus to collaborate on biosimilars []. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 29]. Available from: 
2.   GaBI Online - Generics and Biosimilars Initiative. Etanercept biosimilar has comparable pharmacokinetics to Enbrel []. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 29]. Available from: 
3.   GaBI Online - Generics and Biosimilars Initiative. Coherus starts phase III biosimilar etanercept trial []. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 29]. Available from: 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Coherus

comment icon Comments (0)
Post your comment
Related content
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010